Scipher Medicine Appoints Richard Blackburn to its Advisory Board

Richard Blackburn

Former Pfizer Global President for Inflammation and Immunology Joins Growing Precision Immunology Company 

WALTHAM, Mass. (December 16, 2021) - Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced the appointment of Richard Blackburn to its advisory board.  

Blackburn spent more than three decades at Sterling-Winthrop, Sanofi, Parke-Davis, and Pfizer. Most recently he was global president for Inflammation and Immunology at Pfizer, leading its multi-billion-dollar therapeutic business in autoimmune diseases. 

“Finding the right medicine for patients with autoimmune conditions is difficult and often relies on trial and error, which takes time, consumes resources and, most importantly, delays the improvement so desperately needed by people suffering from these diseases,” said Blackburn. “Scipher Medicine is bringing forward innovative precision medicine solutions that benefit patients, physicians, and the healthcare system. I’m proud to be a part of this important mission.”  

“We are pleased to welcome Richard to the team,” said Alif Saleh, chief executive officer of Scipher Medicine. “His experience in the autoimmune drug markets will greatly benefit the team and our ability to navigate the healthcare system to ensure our precision medicine solutions reach all patients.”  

Blackburn’s addition to the advisory board follows last month’s appointment of pharma leader Dr. Michael Elliott, former senior vice president of Immunology at Janssen Pharmaceuticals. 

About Scipher Medicine®  

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, our proprietary network medicine platform, we commercialize tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, health care providers, and pharmaceutical companies to bring solutions to patients with autoimmune diseases. Visit and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.


Media Relations 
Matt Burns 
VP, Head of Communications 

Investor Relations 
John Strumbos, Ph.D., MBA 
Chief Financial Officer